Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies
暂无分享,去创建一个
I. Yanatori | D. Richardson | R. Quinn | G. Mellick | K. Tonissen | D. Pountney | V. Richardson | L. Ma | M. Dharmasivam | Y. Feng | M. Gholam Azad | Y. Feng | Y. Feng | Y. Feng
[1] A. Lambeir,et al. Metal ions shape α-synuclein , 2020, Scientific Reports.
[2] D. Richardson,et al. The anti-tumor agent, Dp44mT, promotes nuclear translocation of TFEB via inhibition of the AMPK-MTORC1 axis. , 2020, Biochimica et biophysica acta. Molecular basis of disease.
[3] R. Chung,et al. Extracellular Alpha-Synuclein Promotes a Neuroinhibitory Secretory Phenotype in Astrocytes , 2020, Life.
[4] C. Cahill,et al. Iron-responsive-like elements and neurodegenerative ferroptosis , 2020, Learning & memory.
[5] I. Yanatori,et al. The new role of poly (rC)-binding proteins as Iron transport chaperones: Proteins that could couple with inter-organelle interactions to safely traffic iron. , 2020, Biochimica et biophysica acta. General subjects.
[6] D. Richardson,et al. Acireductone dioxygenase 1 (ADI1) is regulated by cellular iron by a mechanism involving the iron chaperone, PCBP1, with PCBP2 acting as a potential co-chaperone. , 2020, Biochimica et biophysica acta. Molecular basis of disease.
[7] I. Yanatori,et al. Ferroptosis at the crossroads of infection, aging and cancer , 2020, Cancer science.
[8] F. Salachas,et al. Conservative iron chelation for neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis , 2020, Journal of Neural Transmission.
[9] Walter N. Moss,et al. Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA , 2020, Proceedings of the National Academy of Sciences.
[10] D. Richardson,et al. Regulation of autophagy and apoptosis by Dp44mT-mediated activation of AMPK in pancreatic cancer cells. , 2020, Biochimica et biophysica acta. Molecular basis of disease.
[11] S. Egan,et al. Novel multifunctional iron chelators of the aroyl nicotinoyl hydrazone class that markedly enhance cellular NAD+/NADH ratios , 2020, British journal of pharmacology.
[12] T. Niki,et al. DJ-1-binding compound B enhances Nrf2 activity through the PI3-kinase-Akt pathway by DJ-1-dependent inactivation of PTEN , 2019, Brain Research.
[13] I. Yanatori,et al. How iron is handled in the course of heme catabolism: Integration of heme oxygenase with intracellular iron transport mechanisms mediated by poly (rC)-binding protein-2. , 2019, Archives of biochemistry and biophysics.
[14] R. Olsthoorn,et al. Relevance of the iron-responsive element (IRE) pseudotriloop structure for IRP1/2 binding and validation of IRE-like structures using the yeast three-hybrid system. , 2019, Gene.
[15] A. Vashisht,et al. A PCBP1–BolA2 chaperone complex delivers iron for cytosolic [2Fe–2S] cluster assembly , 2019, Nature Chemical Biology.
[16] Haiyan Zhang,et al. Identification of a New α-Synuclein Aggregation Inhibitor via Mass Spectrometry-based Screening. , 2019, ACS chemical neuroscience.
[17] T. Hofer,et al. Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification. , 2019, Journal of inorganic biochemistry.
[18] V. Zinchenko,et al. Role of DJ-1 in the mechanism of pathogenesis of Parkinson's disease , 2019, Journal of Bioenergetics and Biomembranes.
[19] Alessandro Arcovito,et al. Cryo-EM structure of the human ferritin–transferrin receptor 1 complex , 2019, Nature Communications.
[20] M. Knutson. Non-transferrin-bound iron transporters. , 2019, Free radical biology & medicine.
[21] I. Yanatori,et al. DMT1 and iron transport , 2019, Free radical biology & medicine.
[22] H. Kawabata. Transferrin and transferrin receptors update , 2019, Free radical biology & medicine.
[23] B. Gallie,et al. Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox , 2019, PloS one.
[24] J. Morales-Garcia,et al. Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease , 2019, International journal of molecular sciences.
[25] M. Goulding,et al. Switching on Endogenous Metal Binding Proteins in Parkinson’s Disease , 2019, Cells.
[26] Donna D. Zhang,et al. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis , 2019, Redox biology.
[27] M. Marinelli. Dopamine , 2018, Reactions Weekly.
[28] Haniye Sadat Sajadi,et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, The Lancet.
[29] J. Mancias,et al. The Role of NCOA4-Mediated Ferritinophagy in Health and Disease , 2018, Pharmaceuticals.
[30] M. Youdim. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases , 2018, Journal of Neural Transmission.
[31] L. Ruiz,et al. The Interplay among PINK1/PARKIN/Dj-1 Network during Mitochondrial Quality Control in Cancer Biology: Protein Interaction Analysis , 2018, Cells.
[32] A. Zeidan,et al. To chelate or not to chelate in MDS: That is the question! , 2018, Blood reviews.
[33] Yoshiro Saito,et al. Distribution of oxidized DJ-1 in Parkinson’s disease-related sites in the brain and in the peripheral tissues: effects of aging and a neurotoxin , 2018, Scientific Reports.
[34] R. Liddle. Parkinson’s disease from the gut , 2018, Brain Research.
[35] S. Ballas,et al. The effect of iron chelation therapy on overall survival in sickle cell disease and β‐thalassemia: A systematic review , 2018, American journal of hematology.
[36] H. Lodish,et al. Critical Issues in Diamond-Blackfan Anemia and Prospects for Novel Treatment. , 2018, Hematology/oncology clinics of North America.
[37] S. Chirumbolo,et al. Metals and Parkinson's Disease: Mechanisms and Biochemical Processes. , 2018, Current medicinal chemistry.
[38] N. Braidy,et al. Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer's disease. , 2018, Dalton transactions.
[39] Carolyn M. Sue,et al. Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives , 2018, Current Neurology and Neuroscience Reports.
[40] P. Pagliaro,et al. Redox Aspects of Chaperones in Cardiac Function , 2018, Front. Physiol..
[41] M. Sitti,et al. Redox metals homeostasis in multiple sclerosis and amyotrophic lateral sclerosis: a review , 2018, Cell Death & Disease.
[42] Junxia Xie,et al. New Progress on the Role of Glia in Iron Metabolism and Iron-Induced Degeneration of Dopamine Neurons in Parkinson’s Disease , 2018, Front. Mol. Neurosci..
[43] L. Defebvre,et al. Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? , 2017, Antioxidants & redox signaling.
[44] T. Claudepierre,et al. Cellular and Molecular Aspects of the β-N-Methylamino-l-alanine (BMAA) Mode of Action within the Neurodegenerative Pathway: Facts and Controversy , 2017, Toxins.
[45] Simon C Watkins,et al. PEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals , 2017, Cell.
[46] Neena Singh,et al. α-Synuclein impairs ferritinophagy in the retinal pigment epithelium: Implications for retinal iron dyshomeostasis in Parkinson’s disease , 2017, Scientific Reports.
[47] W. Gu,et al. NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression. , 2017, Molecular cell.
[48] J. Andersen,et al. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo , 2017, Neuropharmacology.
[49] Tadeusz Sarna,et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease , 2017, Progress in Neurobiology.
[50] Megan Lee,et al. Effectiveness of physical activity on patients with depression and Parkinson's disease: A systematic review , 2017, PloS one.
[51] David M. Shackleford,et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease , 2017, Acta neuropathologica communications.
[52] I. Yanatori,et al. The iron chaperone poly(rC)-binding protein 2 forms a metabolon with the heme oxygenase 1/cytochrome P450 reductase complex for heme catabolism and iron transfer , 2017, The Journal of Biological Chemistry.
[53] Yukio Nakamura,et al. A specialized pathway for erythroid iron delivery through lysosomal trafficking of transferrin receptor 2. , 2017, Blood advances.
[54] R. Nussbaum,et al. α-Synuclein in gut endocrine cells and its implications for Parkinson's disease. , 2017, JCI insight.
[55] Qiangqiang Liu,et al. New tris(dopamine) derivative as an iron chelator. Synthesis, solution thermodynamic stability, and antioxidant research. , 2017, Journal of inorganic biochemistry.
[56] P. Whitley,et al. Steady-State Kinetics of α-Synuclein Ferrireductase Activity Identifies the Catalytically Competent Species. , 2017, Biochemistry.
[57] Maneesh C. Patel,et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease , 2017, Scientific Reports.
[58] D. Yanagisawa,et al. Mitochondrial ferritin protects SH-SY5Y cells against H2O2-induced oxidative stress and modulates α-synuclein expression , 2017, Experimental Neurology.
[59] Scott J. Dixon,et al. Ferroptosis: bug or feature? , 2017, Immunological reviews.
[60] C. Philpott,et al. PCBP1 and NCOA4 regulate erythroid iron storage and heme biosynthesis , 2017, The Journal of clinical investigation.
[61] D. Wink,et al. Regulation and control of nitric oxide (NO) in macrophages: Protecting the "professional killer cell" from its own cytotoxic arsenal via MRP1 and GSTP1. , 2017, Biochimica et biophysica acta. General subjects.
[62] N. Rouach,et al. Human astrocytes: structure and functions in the healthy brain , 2017, Brain Structure and Function.
[63] G. Mellick,et al. Role of the VPS35 D620N mutation in Parkinson's disease. , 2017, Parkinsonism & related disorders.
[64] C. Achat-Mendes,et al. Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator , 2017, Neural regeneration research.
[65] P. Lingor,et al. Alpha-synuclein and iron: two keys unlocking Parkinson’s disease , 2017, Journal of Neural Transmission.
[66] M. Reith,et al. A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson's Disease. , 2017, ACS chemical neuroscience.
[67] A. Mason,et al. Erythroid cell mitochondria receive endosomal iron by a "kiss-and-run" mechanism. , 2016, Biochimica et biophysica acta.
[68] D. Richardson,et al. The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells. , 2016, Biochimica et biophysica acta.
[69] D. Richardson,et al. A Nitric Oxide Storage and Transport System That Protects Activated Macrophages from Endogenous Nitric Oxide Cytotoxicity* , 2016, The Journal of Biological Chemistry.
[70] A. Mason,et al. Endosome–mitochondria interactions are modulated by iron release from transferrin , 2016, The Journal of cell biology.
[71] Ferdinand Schweser,et al. Quantitative Susceptibility Mapping in Parkinson's Disease , 2016, PloS one.
[72] Neena Singh,et al. Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: Implications for visual manifestations of Parkinson's disease. , 2016, Free radical biology & medicine.
[73] K. Chaudhuri,et al. New concepts in the pathogenesis and presentation of Parkinson's disease. , 2016, Clinical medicine.
[74] O. Schueler‐Furman,et al. Parkin Somatic Mutations Link Melanoma and Parkinson's Disease. , 2016, Journal of genetics and genomics = Yi chuan xue bao.
[75] I. Yanatori,et al. Iron Export through the Transporter Ferroportin 1 Is Modulated by the Iron Chaperone PCBP2* , 2016, The Journal of Biological Chemistry.
[76] D. Richardson,et al. Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase. , 2016, Biochemical pharmacology.
[77] Wen-Chang Chang,et al. Paraquat Induces Cell Death Through Impairing Mitochondrial Membrane Permeability , 2016, Molecular Neurobiology.
[78] S. Dixon,et al. Mechanisms of ferroptosis , 2016, Cellular and Molecular Life Sciences.
[79] Yonatan Stelzer,et al. Parkinson-associated risk variant in enhancer element produces subtle effect on target gene expression , 2016, Nature.
[80] R. Ortega,et al. α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons , 2016, Molecular Neurobiology.
[81] G. Kontoghiorghes,et al. New developments and controversies in iron metabolism and iron chelation therapy. , 2016, World journal of methodology.
[82] Xiao-Xing Li,et al. Rab1 in Cell Signaling, Cancer and Other Diseases , 2016, Oncogene.
[83] Dipendra K. Aryal,et al. Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice , 2016, Proceedings of the National Academy of Sciences.
[84] M. Castro,et al. Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative Disorders , 2015, International journal of molecular sciences.
[85] S. Biswas,et al. The regulation of p53 up‐regulated modulator of apoptosis by JNK/c‐Jun pathway in β‐amyloid‐induced neuron death , 2015, Journal of neurochemistry.
[86] A. Bush,et al. Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse , 2015, Neurobiology of Disease.
[87] M. Núñez,et al. The novel mitochondrial iron chelator 5-((methylamino)methyl)-8-hydroxyquinoline protects against mitochondrial-induced oxidative damage and neuronal death. , 2015, Biochemical and biophysical research communications.
[88] Suneil K. Kalia,et al. α-Synuclein and Lewy pathology in Parkinson's disease. , 2015, Current opinion in neurology.
[89] H. Lashuel,et al. Elucidating the Role of Site-Specific Nitration of α-Synuclein in the Pathogenesis of Parkinson's Disease via Protein Semisynthesis and Mutagenesis. , 2015, Journal of the American Chemical Society.
[90] M. Sharon,et al. The Parkinson’s-associated protein DJ-1 regulates the 20S proteasome , 2015, Nature Communications.
[91] Richard Wade-Martins,et al. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. , 2015, Trends in biochemical sciences.
[92] D. Richardson,et al. Duodenal Cytochrome b (DCYTB) in Iron Metabolism: An Update on Function and Regulation , 2015, Nutrients.
[93] P. Spano,et al. Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? , 2015, Parkinson's disease.
[94] W. Gu,et al. Ferroptosis as a p53-mediated activity during tumour suppression , 2015, Nature.
[95] P. Lingor,et al. Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease. , 2015, Metallomics : integrated biometal science.
[96] J. Vickers,et al. The degree of astrocyte activation in multiple system atrophy is inversely proportional to the distance to α-synuclein inclusions , 2015, Molecular and Cellular Neuroscience.
[97] N. Calakos,et al. Neuroepithelial circuit formed by innervation of sensory enteroendocrine cells. , 2015, The Journal of clinical investigation.
[98] R. Youle,et al. The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease , 2015, Neuron.
[99] G. Petsko,et al. Transnitrosylation from DJ-1 to PTEN Attenuates Neuronal Cell Death in Parkinson's Disease Models , 2014, The Journal of Neuroscience.
[100] Jonghan Kim,et al. Iron and mechanisms of emotional behavior. , 2014, The Journal of nutritional biochemistry.
[101] S. Goswami,et al. SG2NA recruits DJ-1 and Akt into the mitochondria and membrane to protect cells from oxidative damage. , 2014, Free radical biology & medicine.
[102] D. Richardson,et al. Glutathione S-transferase and MRP1 form an integrated system involved in the storage and transport of dinitrosyl-dithiolato iron complexes in cells. , 2014, Free radical biology & medicine.
[103] D. Richardson,et al. The active role of vitamin C in mammalian iron metabolism: much more than just enhanced iron absorption! , 2014, Free radical biology & medicine.
[104] I. Yanatori,et al. Chaperone protein involved in transmembrane transport of iron. , 2014, The Biochemical journal.
[105] M. Marsella,et al. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. , 2014, Hematology/oncology clinics of North America.
[106] Neena Singh,et al. Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease. , 2014, Antioxidants & redox signaling.
[107] DuhamelAlain,et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. , 2014 .
[108] M. O’Banion,et al. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed , 2014, Journal of Neuroinflammation.
[109] F. Wang,et al. Role and Mechanism of Microglial Activation in Iron-Induced Selective and Progressive Dopaminergic Neurodegeneration , 2014, Molecular Neurobiology.
[110] S. Rivella,et al. IDENTIFICATION OF ERYTHROFERRONE AS AN ERYTHROID REGULATOR OF IRON METABOLISM , 2014, Nature Genetics.
[111] Blaine R. Roberts,et al. An iron–dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta , 2014 .
[112] K. Tsumoto,et al. Thermodynamic and structural characterization of the specific binding of Zn(II) to human protein DJ-1. , 2014, Biochemistry.
[113] S. Gygi,et al. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy , 2014, Nature.
[114] L. Bubacco,et al. DJ-1 Is a Copper Chaperone Acting on SOD1 Activation* , 2014, The Journal of Biological Chemistry.
[115] Matthew E. Welsch,et al. Regulation of Ferroptotic Cancer Cell Death by GPX4 , 2014, Cell.
[116] Eberhard O Voit,et al. Rotenone and paraquat perturb dopamine metabolism: A computational analysis of pesticide toxicity. , 2014, Toxicology.
[117] A. Munnich,et al. Regional siderosis: a new challenge for iron chelation therapy , 2013, Front. Pharmacol..
[118] R. Edwards,et al. The Function of α-Synuclein , 2013, Neuron.
[119] Ke Xu,et al. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients. , 2013, Magnetic resonance imaging.
[120] S. Mandel,et al. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. , 2013, Free radical biology & medicine.
[121] F. Codazzi,et al. Iron uptake in quiescent and inflammation-activated astrocytes: A potentially neuroprotective control of iron burden , 2013, Biochimica et biophysica acta.
[122] M. Sari,et al. Hepcidin Bound to α2-Macroglobulin Reduces Ferroportin-1 Expression and Enhances Its Activity at Reducing Serum Iron Levels , 2013, The Journal of Biological Chemistry.
[123] X. Xu,et al. Parkinson Disease Protein DJ-1 Binds Metals and Protects against Metal-induced Cytotoxicity* , 2013, The Journal of Biological Chemistry.
[124] D. Richardson,et al. Transferrin iron uptake is stimulated by ascorbate via an intracellular reductive mechanism. , 2013, Biochimica et biophysica acta.
[125] P. Subramanian,et al. Each Member of the Poly-r(C)-binding Protein 1 (PCBP) Family Exhibits Iron Chaperone Activity toward Ferritin* , 2013, The Journal of Biological Chemistry.
[126] Hitoshi Takahashi,et al. The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders , 2013, Molecular Neurobiology.
[127] J. Bonny,et al. Is R2* a New MRI Biomarker for the Progression of Parkinson’s Disease? A Longitudinal Follow-Up , 2013, PloS one.
[128] K. Nakao,et al. Secreted protein lipocalin‐2 promotes microglial M1 polarization , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[129] D. Hinkle,et al. DJ-1 Expression Modulates Astrocyte-Mediated Protection Against Neuronal Oxidative Stress , 2013, Journal of Molecular Neuroscience.
[130] P. Buehler,et al. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. , 2013, Blood.
[131] P. Bradford,et al. L-Arginine and Nitric Oxide in CNS Function and Neurodegenerative Diseases , 2013, Critical reviews in food science and nutrition.
[132] Lucía Gutiérrez,et al. Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia , 2012, Proceedings of the National Academy of Sciences.
[133] J. Trojanowski,et al. Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.
[134] R. Eisenstein,et al. Mammalian iron metabolism and its control by iron regulatory proteins. , 2012, Biochimica et biophysica acta.
[135] F. Loreni,et al. &agr;-Synuclein expression is modulated at the translational level by iron , 2012, Neuroreport.
[136] Peter Teismann,et al. Chelators in the Treatment of Iron Accumulation in Parkinson's Disease , 2012, International journal of cell biology.
[137] N. Greig,et al. The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5′Untranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression , 2012, Parkinson's disease.
[138] M. R. Lamprecht,et al. Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.
[139] S. David,et al. Iron Efflux from Astrocytes Plays a Role in Remyelination , 2012, The Journal of Neuroscience.
[140] M. Kotze,et al. The conundrum of iron in multiple sclerosis – time for an individualised approach , 2012, Metabolic Brain Disease.
[141] J. Connor,et al. Functional roles of transferrin in the brain. , 2012, Biochimica et biophysica acta.
[142] T. Mak,et al. Consequences of DJ-1 upregulation following p53 loss and cell transformation , 2012, Oncogene.
[143] S. Cha,et al. YajL, Prokaryotic Homolog of Parkinsonism-associated Protein DJ-1, Functions as a Covalent Chaperone for Thiol Proteome* , 2011, The Journal of Biological Chemistry.
[144] D. Richardson,et al. Nitric Oxide Storage and Transport in Cells Are Mediated by Glutathione S-Transferase P1-1 and Multidrug Resistance Protein 1 via Dinitrosyl Iron Complexes* , 2011, The Journal of Biological Chemistry.
[145] S. Bruley des Varannes,et al. Parkinson disease , 2011, Neurology.
[146] G. Semenza,et al. Hypoxia‐inducible factor 1 mediates increased expression of NADPH oxidase‐2 in response to intermittent hypoxia , 2011, Journal of cellular physiology.
[147] Jason R. Hickok,et al. Dinitrosyliron complexes are the most abundant nitric oxide-derived cellular adduct: biological parameters of assembly and disappearance. , 2011, Free radical biology & medicine.
[148] M. Farrer,et al. VPS35 mutations in Parkinson disease. , 2011, American journal of human genetics.
[149] D. Dickson,et al. Neuropathology underlying clinical variability in patients with synucleinopathies , 2011, Acta Neuropathologica.
[150] M. Wilson. The role of cysteine oxidation in DJ-1 function and dysfunction. , 2011, Antioxidants & redox signaling.
[151] D. Richardson,et al. The Potent and Novel Thiosemicarbazone Chelators Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-Benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone Affect Crucial Thiol Systems Required for Ribonucleotide Reductase Activity , 2011, Molecular Pharmacology.
[152] H. Adami,et al. Epidemiology and etiology of Parkinson’s disease: a review of the evidence , 2011, European Journal of Epidemiology.
[153] R. Armstrong,et al. Visual Symptoms in Parkinson's Disease , 2011, Parkinson's disease.
[154] D. Maraganore. Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease , 2011, Journal of movement disorders.
[155] S. Daubner,et al. Tyrosine hydroxylase and regulation of dopamine synthesis. , 2011, Archives of biochemistry and biophysics.
[156] G. Semenza,et al. Hypoxia‐Inducible Factor 1 Mediates Increased Expression of NADPH Oxidase‐2 in Response to Intermittent Hypoxia , 2011 .
[157] S. Robinson,et al. Accumulation of Non-Transferrin-Bound Iron by Neurons, Astrocytes, and Microglia , 2011, Neurotoxicity Research.
[158] T. Tweed. Space , 2011, STEM Education in the Primary School.
[159] Junxia Xie,et al. Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells , 2011, Journal of Neural Transmission.
[160] S. Aquilonius,et al. Manganese-Induced Parkinsonism due to Ephedrone Abuse , 2011, Parkinson's disease.
[161] Fred H. Gage,et al. In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.
[162] T. Iancu. Ultrastructural aspects of iron storage, transport and metabolism , 2011, Journal of Neural Transmission.
[163] P. Brundin,et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. , 2011, The Journal of clinical investigation.
[164] L. Della Corte,et al. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration , 2011, Journal of Neural Transmission.
[165] David R. Brown,et al. Correction: Alpha-Synuclein Is a Cellular Ferrireductase , 2011, PLoS ONE.
[166] Philip L De Jager,et al. Parkinson's disease: genetics and pathogenesis. , 2011, Annual review of pathology.
[167] A. Manning-Boğ,et al. Glutathione Peroxidase 4 is associated with Neuromelanin in Substantia Nigra and Dystrophic Axons in Putamen of Parkinson's brain , 2011, Molecular Neurodegeneration.
[168] N. Greig,et al. The alpha-synuclein 5′untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen , 2011, Journal of Neural Transmission.
[169] S. Cragg,et al. α-Synuclein and dopamine at the crossroads of Parkinson's disease , 2010, Trends in Neurosciences.
[170] Paul T. Schumacker,et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1 , 2010, Nature.
[171] Xudong Huang,et al. Selective Translational Control of the Alzheimer Amyloid Precursor Protein Transcript by Iron Regulatory Protein-1*♦ , 2010, The Journal of Biological Chemistry.
[172] L. Chin,et al. Parkinson disease protein DJ-1 converts from a zymogen to a protease by carboxyl-terminal cleavage. , 2010, Human molecular genetics.
[173] S. Robinson,et al. Synergistic accumulation of iron and zinc by cultured astrocytes , 2010, Journal of Neural Transmission.
[174] M. Farrer,et al. Missing pieces in the Parkinson's disease puzzle , 2010, Nature Medicine.
[175] D. Richardson,et al. Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol , 2010, Proceedings of the National Academy of Sciences.
[176] Beat Meier,et al. Prions , 2010 .
[177] D. Richardson,et al. The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich’s ataxia , 2010, Journal of Molecular Medicine.
[178] Alzheimer’s Association. 2010 Alzheimer's disease facts and figures , 2010, Alzheimer's & Dementia.
[179] W. Seaman,et al. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1 , 2010, Proceedings of the National Academy of Sciences.
[180] S. Murayama,et al. α-SYNUCLEIN ACCUMULATION IN SKIN NERVE FIBERS REVEALED BY SKIN BIOPSY IN PURE AUTONOMIC FAILURE , 2010, Neurology.
[181] Junxia Xie,et al. Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent , 2010, Cell Research.
[182] 郑莉,et al. HePcidin的临床研究进展 , 2010 .
[183] Junxia Xie,et al. Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease. , 2010, Free radical biology & medicine.
[184] E. Masliah,et al. Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies* , 2010, The Journal of Biological Chemistry.
[185] P. Brundin,et al. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. , 2009, Parkinsonism & related disorders.
[186] D. Dickson,et al. Neuropathology of non-motor features of Parkinson disease. , 2009, Parkinsonism & related disorders.
[187] E. Wolters. Non-motor extranigral signs and symptoms in Parkinson's disease. , 2009, Parkinsonism & related disorders.
[188] David N. Powers,et al. Control of Iron Homeostasis by an Iron-Regulated Ubiquitin Ligase , 2009, Science.
[189] Sonja W. Scholz,et al. Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.
[190] D. Richardson,et al. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant , 2009, Proceedings of the National Academy of Sciences.
[191] Hong Jiang,et al. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis in MES23.5 cells , 2009, Neurobiology of Aging.
[192] M. Beal,et al. Inhibition of Prolyl Hydroxylase Protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity , 2009, The Journal of Biological Chemistry.
[193] C. Colton. Heterogeneity of Microglial Activation in the Innate Immune Response in the Brain , 2009, Journal of Neuroimmune Pharmacology.
[194] Brian Spencer,et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.
[195] S. Prusiner,et al. Is Parkinson's disease a prion disorder? , 2009, Proceedings of the National Academy of Sciences.
[196] J. Im,et al. Repression of α-synuclein expression and toxicity by microRNA-7 , 2009, Proceedings of the National Academy of Sciences.
[197] D. Richardson,et al. Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): no overt alteration in phenotype. , 2009, Biochimica et biophysica acta.
[198] R. Petersen,et al. Prion Protein (PrP) Knock-Out Mice Show Altered Iron Metabolism: A Functional Role for PrP in Iron Uptake and Transport , 2009, PloS one.
[199] P. Kuchel,et al. Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. , 2009, Blood.
[200] J. Trojanowski,et al. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease , 2009, Neurobiology of Disease.
[201] Xiaomin Su,et al. Mutant α-Synuclein Overexpression Mediates Early Proinflammatory Activity , 2009, Neurotoxicity Research.
[202] B. Todorich,et al. Oligodendrocytes and myelination: The role of iron , 2009, Glia.
[203] Mark A. Wilson,et al. Formation of a Stabilized Cysteine Sulfinic Acid Is Critical for the Mitochondrial Function of the Parkinsonism Protein DJ-1* , 2009, Journal of Biological Chemistry.
[204] N. Greig,et al. Physiological and Pathological Role of Alpha-synuclein in Parkinson’s Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element , 2009, International journal of molecular sciences.
[205] F. Othman,et al. An anticancer agent , 2009 .
[206] M. Cookson. α-Synuclein and neuronal cell death , 2009, Molecular Neurodegeneration.
[207] D. Selkoe,et al. α‐Synuclein and Polyunsaturated Fatty Acids Promote Clathrin‐Mediated Endocytosis and Synaptic Vesicle Recycling , 2009, Traffic.
[208] F. Fujiyama,et al. Single Nigrostriatal Dopaminergic Neurons Form Widely Spread and Highly Dense Axonal Arborizations in the Neostriatum , 2009, The Journal of Neuroscience.
[209] J. Stankiewicz,et al. Role of iron in neurotoxicity: a cause for concern in the elderly? , 2009, Current opinion in clinical nutrition and metabolic care.
[210] T. Dawson,et al. What causes cell death in Parkinson's disease? , 2008, Annals of neurology.
[211] J. Beard,et al. Dopamine D2 receptor expression is altered by changes in cellular iron levels in PC12 cells and rat brain tissue. , 2008, The Journal of nutrition.
[212] B. Todorich,et al. Tim‐2 is the receptor for H‐ferritin on oligodendrocytes , 2008, Journal of neurochemistry.
[213] N. Cole. Metal catalyzed oxidation of alpha-synuclein--a role for oligomerization in pathology? , 2008, Current Alzheimer research.
[214] Charles Duyckaerts,et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease , 2008, Proceedings of the National Academy of Sciences.
[215] Sharad Kumar,et al. Regulation of the divalent metal ion transporter DMT1 and iron homeostasis by a ubiquitin-dependent mechanism involving Ndfips and WWP2. , 2008, Blood.
[216] N. Turro,et al. New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals , 2008, Proceedings of the National Academy of Sciences.
[217] Martyn N J Paley,et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease , 2008, Journal of magnetic resonance imaging : JMRI.
[218] T. Iwatsubo,et al. Lewy Body Pathology Involves Cutaneous Nerves , 2008, Journal of neuropathology and experimental neurology.
[219] Yong Tong,et al. Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease. , 2008, Current bioactive compounds.
[220] Tianhong Pan,et al. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. , 2008, Brain : a journal of neurology.
[221] Ming Zhan,et al. RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways , 2008, Proceedings of the National Academy of Sciences.
[222] D. Richardson,et al. The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation , 2008, Proceedings of the National Academy of Sciences.
[223] D. Sulzer,et al. Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease , 2008, Journal of neurochemistry.
[224] T. Stemmler,et al. A Cytosolic Iron Chaperone That Delivers Iron to Ferritin , 2008, Science.
[225] D. Berg,et al. Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[226] R. Perez,et al. α-Synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: Lessons from viral transduction of knockout mice , 2008, Neuroscience Letters.
[227] P. Chan,et al. Silencing α-Synuclein Gene Expression Enhances Tyrosine Hydroxylase Activity in MN9D Cells , 2008, Neurochemical Research.
[228] P. Vieregge. [Idiopathic Parkinson's disease]. , 2008, Fortschritte der Neurologie-Psychiatrie.
[229] A. Schapira. Mitochondria in the aetiology and pathogenesis of Parkinson's disease , 2008, The Lancet Neurology.
[230] N. Gao,et al. Effect of α-synuclein on the promoter activity of tyrosine hydroxylase gene , 2007, Neuroscience Bulletin.
[231] J. Jankovic,et al. Prevention and restoration of lactacystin‐induced nigrostriatal dopamine neuron degeneration by novel brain‐permeable iron chelators , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[232] E. Morgan,et al. Iron trafficking inside the brain , 2007, Journal of neurochemistry.
[233] D. Richardson,et al. Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo. , 2007, Carcinogenesis.
[234] D. Richardson,et al. The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark – from iron metabolism to tumorigenesis , 2007, Oncogene.
[235] T. Dawson,et al. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase , 2007, Proceedings of the National Academy of Sciences.
[236] D. Richardson,et al. Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity. , 2007, Dalton transactions.
[237] Bharathi,et al. Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease. , 2007, Biochemical and biophysical research communications.
[238] D. Richardson,et al. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. , 2007, Blood.
[239] F. Sanvito,et al. Mitochondrial Ferritin Expression in Adult Mouse Tissues , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[240] Nathalie Boddaert,et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. , 2007, Blood.
[241] F. Vallelian,et al. CD163‐expressing monocytes constitute an endotoxin‐sensitive Hb clearance compartment within the vascular system , 2007, Journal of leukocyte biology.
[242] S. Robinson,et al. The Pivotal Role of Astrocytes in the Metabolism of Iron in the Brain , 2007, Neurochemical Research.
[243] Ritwik Ghosh,et al. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. , 2007, Cancer research.
[244] J. Schulz,et al. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.
[245] K. Beyer. Mechanistic aspects of Parkinson’s disease: α-synuclein and the biomembrane , 2007, Cell Biochemistry and Biophysics.
[246] Mayka Sanchez,et al. Iron-regulatory proteins limit hypoxia-inducible factor-2α expression in iron deficiency , 2007, Nature Structural &Molecular Biology.
[247] W. Geldenhuys,et al. Voltage-gated Calcium Channels Provide an Alternate Route for Iron Uptake in Neuronal Cell Cultures , 2007, Neurochemical Research.
[248] R. Tanzi,et al. The 5′-untranslated region of Parkinson's disease α-synuclein messengerRNA contains a predicted iron responsive element , 2007, Molecular Psychiatry.
[249] D. Richardson,et al. Iron uptake and metabolism in the new millennium. , 2007, Trends in cell biology.
[250] J. Wickens,et al. Space, time and dopamine , 2007, Trends in Neurosciences.
[251] P. Várnai,et al. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels , 2006, The Journal of cell biology.
[252] M. Akabas,et al. Identification of an Intestinal Folate Transporter and the Molecular Basis for Hereditary Folate Malabsorption , 2006, Cell.
[253] Claire M. Brown,et al. Direct interorganellar transfer of iron from endosome to mitochondrion. , 2006, Blood.
[254] D. Richardson,et al. The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. , 2006, Carcinogenesis.
[255] M. Kurrer,et al. Constitutive Endocytosis of CD163 Mediates Hemoglobin-Heme Uptake and Determines the Noninflammatory and Protective Transcriptional Response of Macrophages to Hemoglobin , 2006, Circulation research.
[256] D. Rubinsztein,et al. The roles of intracellular protein-degradation pathways in neurodegeneration , 2006, Nature.
[257] M. Beal,et al. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.
[258] J. Trojanowski,et al. Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery , 2006, Neuron.
[259] D. Richardson,et al. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics , 2006, Proceedings of the National Academy of Sciences.
[260] Aldo Quattrone,et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. , 2006, JAMA.
[261] K. Xia,et al. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. , 2006, Human molecular genetics.
[262] D. Richardson,et al. Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1 , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[263] J. Xie,et al. Parkinson's Disease Brain Mitochondrial Complex I Has Oxidatively Damaged Subunits and Is Functionally Impaired and Misassembled , 2006, The Journal of Neuroscience.
[264] L. Zecca,et al. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability , 2006, Journal of Neural Transmission.
[265] Louise K. Charkoudian,et al. Fe(III)-coordination properties of neuromelanin components: 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid. , 2006, Inorganic chemistry.
[266] D. Richardson,et al. Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. , 2006, Blood.
[267] 간다 유타카,et al. Anti-tumor agent , 2006 .
[268] D. Richardson,et al. The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer , 2005, Pharmacological Reviews.
[269] G. Cha,et al. Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. , 2005, Gene.
[270] C. Ross,et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[271] J. J. Sharp,et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells , 2005, Nature Genetics.
[272] D. Berg,et al. In vivo detection of iron and neuromelanin by transcranial sonography: A new approach for early detection of substantia nigra damage , 2005, Movement disorders : official journal of the Movement Disorder Society.
[273] C. Vulpe,et al. Identification of an Intestinal Heme Transporter , 2005, Cell.
[274] L. Stefanis,et al. α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells , 2005, Journal of Cell Science.
[275] Reidun Torp,et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. , 2005, Human molecular genetics.
[276] R. Barker,et al. Skin and platelet α-synuclein as peripheral biomarkers of Parkinson's disease , 2005, Neuroscience Letters.
[277] David S. Park,et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[278] David W. Miller,et al. Effects of DJ-1 mutations and polymorphisms on protein stability and subcellular localization. , 2005, Brain research. Molecular brain research.
[279] C. Griesinger,et al. Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[280] D. Richardson,et al. Iron trafficking in the mitochondrion: novel pathways revealed by disease. , 2005, Blood.
[281] J. Andersen,et al. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO‐mediated pathway not involving peroxynitrite: implications for Parkinson's disease , 2005, Journal of neurochemistry.
[282] E. Beutler,et al. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. , 2005, Blood cells, molecules & diseases.
[283] P. Calabresi,et al. Nigrostriatal Dopaminergic Deficits and Hypokinesia Caused by Inactivation of the Familial Parkinsonism-Linked Gene DJ-1 , 2005, Neuron.
[284] P. Riederer,et al. Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease , 2005, Progress in Neurobiology.
[285] Jerry Kaplan,et al. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.
[286] Alberto Albertini,et al. The neuromelanin of human substantia nigra: physiological and pathogenic aspects. , 2004, Pigment cell research.
[287] Guangjun Nie,et al. Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. , 2004, Blood.
[288] D. Richardson,et al. The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. , 2004, Biochimica et biophysica acta.
[289] D. Richardson,et al. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. , 2004, Blood.
[290] P. Chan,et al. Inhibition of tyrosine hydroxylase expression in α-synuclein-transfected dopaminergic neuronal cells , 2004, Neuroscience Letters.
[291] Hansjürgen Bratzke,et al. Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.
[292] M. Edwards,et al. Hereditary haemochromatosis is unlikely to cause movement disorders , 2004, Journal of Neurology.
[293] S. Lipton,et al. Molecular pathways to neurodegeneration , 2004, Nature Medicine.
[294] Alberto Gatti,et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[295] Mark A. Wilson,et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[296] T. Hastings,et al. Could a loss of α‐synuclein function put dopaminergic neurons at risk? , 2004 .
[297] J. Nutt,et al. Parkinson's disease , 2004, The Lancet.
[298] R. Nussbaum,et al. Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.
[299] Tomoya Kinumi,et al. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. , 2004, Biochemical and biophysical research communications.
[300] J. Joseph,et al. α-Synuclein Up-regulation and Aggregation during MPP+-induced Apoptosis in Neuroblastoma Cells , 2004, Journal of Biological Chemistry.
[301] V. Subramaniam,et al. Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis. , 2004, Journal of hepatology.
[302] D. Koziorowski,et al. Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra. , 2004, Biochimica et biophysica acta.
[303] D. Richardson. Novel Chelators for Central Nervous System Disorders That Involve Alterations in the Metabolism of Iron and Other Metal Ions , 2004, Annals of the New York Academy of Sciences.
[304] T. Araki,et al. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study , 2004, European Neuropsychopharmacology.
[305] G. Perry,et al. Oxidative Stress and Redox‐Active Iron in Alzheimer's Disease , 2004, Annals of the New York Academy of Sciences.
[306] Keith D Wilkinson,et al. Familial Parkinson's Disease-associated L166P Mutation Disrupts DJ-1 Protein Folding and Function* , 2004, Journal of Biological Chemistry.
[307] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[308] T. Niki,et al. DJ‐1 has a role in antioxidative stress to prevent cell death , 2004, EMBO reports.
[309] M. Youdim,et al. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats , 2004, Neuropharmacology.
[310] W. Jefferies,et al. Identification of a Novel Route of Iron Transcytosis across the Mammalian Blood‐Brain Barrier , 2003, Microcirculation.
[311] E. Morgan,et al. The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain , 2003, Journal of neurochemistry.
[312] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[313] D. Richardson,et al. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. , 2003, Carcinogenesis.
[314] B. Oostra,et al. DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism , 2003, Neurological Sciences.
[315] Serge Gauthier,et al. Expression of melanotransferrin isoforms in human serum: relevance to Alzheimer's disease. , 2003, The Biochemical journal.
[316] K. Jellinger,et al. Neuropathological spectrum of synucleinopathies , 2003, Movement disorders : official journal of the Movement Disorder Society.
[317] Donato A Di Monte,et al. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.
[318] S. David,et al. Glycosylphosphatidylinositol-anchored Ceruloplasmin Is Required for Iron Efflux from Cells in the Central Nervous System* , 2003, Journal of Biological Chemistry.
[319] G. Petsko,et al. The 1.1-Å resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[320] N. Baroukh,et al. Myelination and motor coordination are increased in transferrin transgenic mice , 2003, Journal of neuroscience research.
[321] D. Richardson,et al. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation. , 2003, Carcinogenesis.
[322] G. Fiskum,et al. Mitochondrial Mechanisms of Neural Cell Death and Neuroprotective Interventions in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.
[323] B. Bergamasco,et al. Residual substantia nigra neuromelanin in Parkinson’s disease is cross-linked to α-synuclein , 2003, Neurochemistry International.
[324] Z. Cabantchik,et al. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. , 2003, Blood.
[325] David W. Miller,et al. Co‐ordinate transcriptional regulation of dopamine synthesis genes by α‐synuclein in human neuroblastoma cell lines , 2003, Journal of neurochemistry.
[326] Sonya Cunningham,et al. 1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide. , 2003, The Biochemical journal.
[327] J. Beard,et al. Neonatal iron deficiency results in irreversible changes in dopamine function in rats. , 2003, The Journal of nutrition.
[328] Subramanian Rajagopalan,et al. Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.
[329] Z. Harris. Aceruloplasminemia , 2003, Journal of the Neurological Sciences.
[330] H. Miyajima,et al. Aceruloplasminemia, an inherited disorder of iron metabolism , 2003, Biometals.
[331] M. Cazzola,et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. , 2003, Blood.
[332] Sun-Young Lee,et al. Lipid interaction of α‐synuclein during the metal‐catalyzed oxidation in the presence of Cu2+ and H2O2 , 2003, Journal of neurochemistry.
[333] D. Richardson,et al. Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism: mirror-image effector molecules that target iron. , 2003, The Biochemical journal.
[334] Patrik Brundin,et al. Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein , 2002, Nature Reviews Neuroscience.
[335] Xudong Huang,et al. An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript* , 2002, The Journal of Biological Chemistry.
[336] Patrizia Rizzu,et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.
[337] Richard Paylor,et al. Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.
[338] D. Richardson,et al. The role of iron in cell cycle progression and the proliferation of neoplastic cells. , 2002, Biochimica et biophysica acta.
[339] M. Hentze,et al. Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: Implications for regulation and cellular function , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[340] P. Blumbergs,et al. Nonselenium glutathione peroxidase in human brain : elevated levels in Parkinson's disease and dementia with lewy bodies. , 2002, The American journal of pathology.
[341] T. Niki,et al. DJ-1, a target protein for an endocrine disrupter, participates in the fertilization in mice. , 2002, Biological & pharmaceutical bulletin.
[342] P. Gros,et al. Expression of the iron transporter DMT1 in kidney from normal and anemic mk mice. , 2002, Kidney international.
[343] D. Richardson,et al. The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner. , 2002, European journal of biochemistry.
[344] Bruce A. Yankner,et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.
[345] M. Zigmond,et al. A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.
[346] D. Richardson,et al. The iron metabolism of neoplastic cells: alterations that facilitate proliferation? , 2002, Critical reviews in oncology/hematology.
[347] Paul Alan Cox,et al. Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. , 2002, Neurology.
[348] E. Junn,et al. Human α-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine , 2002, Neuroscience Letters.
[349] Alberto Gatti,et al. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease , 2002, FEBS letters.
[350] M. Hentze,et al. Iron‐dependent regulation of the divalent metal ion transporter , 2001, FEBS letters.
[351] D. Sulzer,et al. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour , 2001, Molecular pathology : MP.
[352] Hiroyoshi Ariga,et al. DJ-1 Positively Regulates the Androgen Receptor by Impairing the Binding of PIASxα to the Receptor* , 2001, The Journal of Biological Chemistry.
[353] Jin Gao,et al. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. , 2001, Blood.
[354] J. Connor,et al. Iron and iron management proteins in neurobiology. , 2001, Pediatric neurology.
[355] J. Beard,et al. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain , 2001, Pharmacology Biochemistry and Behavior.
[356] P. Arosio,et al. A Human Mitochondrial Ferritin Encoded by an Intronless Gene* , 2001, The Journal of Biological Chemistry.
[357] B. Carroll,et al. Serum Melanotransferrin, p97 as a Biochemical Marker of Alzheimer's Disease , 2001, Neuropsychopharmacology.
[358] J. Trojanowski,et al. Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain. , 2001, Parkinsonism & related disorders.
[359] Cornelia M. van Duijn,et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis , 2001, Nature Genetics.
[360] D. Richardson,et al. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. , 2001, Biochimica et biophysica acta.
[361] D. Richardson. The controversial role of deferiprone in the treatment of thalassemia. , 2001, The Journal of laboratory and clinical medicine.
[362] J. Connor,et al. A light and electron microscopic study of the iron transporter protein DMT-1 in the monkey cerebral neocortex and hippocampus , 2001, Journal of neurocytology.
[363] Bruno Turlin,et al. A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload* , 2001, The Journal of Biological Chemistry.
[364] M Gallorini,et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes , 2001, Journal of neurochemistry.
[365] D. Richardson,et al. Nitrogen Monoxide (NO) and Glucose , 2001, The Journal of Biological Chemistry.
[366] R J Simpson,et al. An Iron-Regulated Ferric Reductase Associated with the Absorption of Dietary Iron , 2001, Science.
[367] S. Moestrup,et al. Identification of the haemoglobin scavenger receptor , 2001, Nature.
[368] A. Mitsumoto,et al. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin , 2001, Free radical research.
[369] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[370] P D Griffiths,et al. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. , 2000, Brain : a journal of neurology.
[371] P. Riederer,et al. Structural Characteristics of Human Substantia Nigra Neuromelanin and Synthetic Dopamine Melanins , 2000, Journal of neurochemistry.
[372] P. Lansbury,et al. Accelerated Oligomerization by Parkinson's Disease Linked α‐Synuclein Mutants , 2000 .
[373] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[374] J. Beard,et al. Iron deficiency alters dopamine transporter functioning in rat striatum. , 2000, The Journal of nutrition.
[375] J. Trojanowski,et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.
[376] Sarah J. Tabrizi,et al. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .
[377] L. Greene,et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[378] J. Tateishi,et al. Subacute myelo‐optico‐neuropathy: Clioquinol intoxication in humans and animals , 2000, Neuropathology : official journal of the Japanese Society of Neuropathology.
[379] John Hardy,et al. The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.
[380] S. Abboud,et al. A Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism* , 2000, The Journal of Biological Chemistry.
[381] Hiroshi Kawabata,et al. Transferrin Receptor 2-α Supports Cell Growth Both in Iron-chelated Cultured Cells and in Vivo * , 2000, The Journal of Biological Chemistry.
[382] J. Trojanowski,et al. Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.
[383] J O Rinne,et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. , 2000, Archives of neurology.
[384] D. Richardson,et al. Nitrogen monoxide activates iron regulatory protein 1 RNA-binding activity by two possible mechanisms: effect on the [4Fe-4S] cluster and iron mobilization from cells. , 2000, Biochemistry.
[385] D. Richardson. The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell. , 2000, European journal of biochemistry.
[386] A. Brownlie,et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter , 2000, Nature.
[387] S. David,et al. Alternative RNA Splicing Generates a Glycosylphosphatidylinositol-anchored Form of Ceruloplasmin in Mammalian Brain* , 2000, The Journal of Biological Chemistry.
[388] E. Morgan,et al. Transferrin and Transferrin Receptor Function in Brain Barrier Systems , 2000, Cellular and Molecular Neurobiology.
[389] R J Simpson,et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. , 2000, Molecular cell.
[390] Heidi Phillips,et al. Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.
[391] P. Lansbury,et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[392] D. Richardson. Role of ceruloplasmin and ascorbate in cellular iron release. , 1999, The Journal of laboratory and clinical medicine.
[393] W. Jefferies,et al. Melanotransferrin is produced by senile plaque-associated reactive microglia in Alzheimer's disease , 1999, Brain Research.
[394] P. Thong,et al. Iron and cell death in Parkinson’s disease: a nuclear microscopic study into iron-rich granules in the parkinsonian substantia nigra of primate models , 1999 .
[395] H. Koeffler,et al. Molecular Cloning of Transferrin Receptor 2 , 1999, The Journal of Biological Chemistry.
[396] L. Petrucelli,et al. α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins , 1999, The Journal of Neuroscience.
[397] D. Richardson,et al. The effect of intracellular iron concentration and nitrogen monoxide on Nramp2 expression and non-transferrin-bound iron uptake. , 1999, European journal of biochemistry.
[398] J Kim,et al. Copper(II)-induced self-oligomerization of alpha-synuclein. , 1999, The Biochemical journal.
[399] Masashi Narita,et al. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC , 1999, Nature.
[400] M. Bloom,et al. Identification of a Cell Surface Protein from Crandell Feline Kidney Cells That Specifically Binds Aleutian Mink Disease Parvovirus , 1999, Journal of Virology.
[401] Nancy Andrews,et al. Transferrin receptor is necessary for development of erythrocytes and the nervous system , 1999, Nature Genetics.
[402] C. C. Johnson,et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.
[403] K. Jellinger,et al. The Role of Iron in Neurodegeneration , 1999, Drugs & aging.
[404] Gregory J. Anderson,et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse , 1999, Nature Genetics.
[405] E. Morgan,et al. Evidence for low molecular weight, non‐transferrin‐bound iron in rat brain and cerebrospinal fluid , 1998, Journal of neuroscience research.
[406] Stanley B. Prusiner,et al. Nobel Lecture: Prions , 1998 .
[407] Peter T. Lansbury,et al. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.
[408] Georg Auburger,et al. The ubiquitin pathway in Parkinson's disease , 1998, Nature.
[409] E. Morgan,et al. Expression of the neuronal transferrin receptor is age dependent and susceptible to iron deficiency , 1998, The Journal of comparative neurology.
[410] P. Ponka,et al. Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism , 1998, American journal of hematology.
[411] H. Payami,et al. Genetic Epidemiology of Parkinson's Disease , 1998, Journal of geriatric psychiatry and neurology.
[412] G. Bonvento,et al. Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter: A confocal microscopy study , 1998, Glia.
[413] S. Daniel,et al. Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.
[414] R. Eisenstein,et al. Iron Differentially Stimulates Translation of Mitochondrial Aconitase and Ferritin mRNAs in Mammalian Cells , 1998, The Journal of Biological Chemistry.
[415] N. Andrews,et al. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[416] Olaf Riess,et al. AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.
[417] P. Fox,et al. Role of ceruloplasmin in cellular iron uptake. , 1998, Science.
[418] G. Perry,et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[419] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[420] B. N. Patel,et al. A Novel Glycosylphosphatidylinositol-anchored Form of Ceruloplasmin Is Expressed by Mammalian Astrocytes* , 1997, The Journal of Biological Chemistry.
[421] M. Bradbury. Transport of Iron in the Blood‐Brain‐Cerebrospinal Fluid System , 1997, Journal of neurochemistry.
[422] N. Andrews,et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene , 1997, Nature genetics.
[423] Stephan Nussberger,et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter , 1997, Nature.
[424] B. Bergamasco,et al. EPR investigations of the iron domain in neuromelanin. , 1997, Biochimica et biophysica acta.
[425] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[426] R. Liddington,et al. Raf-1 Kinase and Exoenzyme S Interact with 14-3-3ζ through a Common Site Involving Lysine 49* , 1997, The Journal of Biological Chemistry.
[427] G. Cohen,et al. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[428] D. Richardson,et al. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. , 1997, Blood.
[429] P. Højrup,et al. Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. , 1997, The Biochemical journal.
[430] D. Richardson,et al. Can ferritin provide iron for hemoglobin synthesis? , 1997, Blood.
[431] D. Richardson,et al. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. , 1997, Biochimica et biophysica acta.
[432] T. Taira,et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. , 1997, Biochemical and biophysical research communications.
[433] G. Brittenham,et al. Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.
[434] T. Moos. Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system , 1996, The Journal of comparative neurology.
[435] H. Feldman,et al. Serum levels of the iron binding protein p97 are elevated in Alzheimer′s disease , 1996, Nature Medicine.
[436] R. Broadwell,et al. Transcytosis of Protein through the Mammalian Cerebral Epithelium and Endothelium III. Receptor-Mediated Transcytosis through the Blood–Brain Barrier of Blood-Borne Transferrin and Antibody against the Transferrin Receptor , 1996, Experimental Neurology.
[437] K. Jellinger,et al. Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. , 1996, Biochimica et biophysica acta.
[438] P. Harrison,et al. The ferritins: molecular properties, iron storage function and cellular regulation. , 1996, Biochimica et biophysica acta.
[439] T. Dawson,et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[440] R D Klausner,et al. Differences in the RNA binding sites of iron regulatory proteins and potential target diversity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[441] D. Richardson,et al. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism. , 1996, Blood.
[442] L. Kühn,et al. Iron Regulatory Proteins 1 and 2 Bind Distinct Sets of RNA Target Sequences (*) , 1996, The Journal of Biological Chemistry.
[443] L. Forno,et al. Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.
[444] D. Richardson,et al. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. , 1995, Blood.
[445] B. Deurs,et al. A transferrin-like GPI-linked iron-binding protein in detergent- insoluble noncaveolar microdomains at the apical surface of fetal intestinal epithelial cells , 1995, The Journal of cell biology.
[446] D. Richardson,et al. The effect of redox-related species of nitrogen monoxide on transferrin and iron uptake and cellular proliferation of erythroleukemia (K562) cells. , 1995, Blood.
[447] J. Phillips,et al. Iron Regulates the Intracellular Degradation of Iron Regulatory Protein 2 by the Proteasome (*) , 1995, The Journal of Biological Chemistry.
[448] P. Riederer,et al. Mössbauer Spectroscopic Studies of Purified Human Neuromelanin Isolated from the Substantia Nigra , 1995, Journal of neurochemistry.
[449] R. MacGillivray,et al. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[450] P. Lansbury,et al. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? , 1995, Chemistry & biology.
[451] Akinori Nakamura,et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans , 1995, Nature Genetics.
[452] J. Schulz,et al. Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.
[453] C. Morris,et al. Iron histochemistry of the substantia nigra in Parkinson's disease. , 1994, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[454] D. Richardson,et al. Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake , 1994, Journal of cellular physiology.
[455] C. Marsden,et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.
[456] S. Daniel,et al. Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.
[457] S. Heales,et al. Effects of 1‐Methyl‐4‐Phenylpyridinium on Isolated Rat Brain Mitochondria: Evidence for a Primary Involvement of Energy Depletion , 1994, Journal of neurochemistry.
[458] L. Kühn,et al. Optimal sequence and structure of iron-responsive elements. Selection of RNA stem-loops with high affinity for iron regulatory factor. , 1994, The Journal of biological chemistry.
[459] E. Rosengren,et al. Neuromelanin of the Human Substantia Nigra: A Mixed‐Type Melanin , 1994, Journal of neurochemistry.
[460] R. Ramsay,et al. Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. , 1994, The Journal of biological chemistry.
[461] J. Cooper,et al. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease , 1993, Brain Research.
[462] M. Caron,et al. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[463] R. Broadwell,et al. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. II. Adsorptive transcytosis of WGA-HRP and the blood-brain and brain-blood barriers , 1993, Journal of neurocytology.
[464] R. Klausner,et al. Regulating the fate of mRNA: The control of cellular iron metabolism , 1993, Cell.
[465] E. Morgan,et al. Iron and transferrrin uptake by brain and cerebrospinal fluid in the rat , 1992, Brain Research.
[466] K. Jellinger,et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.
[467] E. Love,et al. Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.
[468] T. S. St. Pierre,et al. A low-spin iron complex in human melanoma and rat hepatoma cells and a high-spin iron(II) complex in rat hepatoma cells. , 1992, Biochimica et biophysica acta.
[469] D. Richardson,et al. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2‐hydroxy‐1‐naphthylaldehyde using the hepatocyte in culture , 1992, Hepatology.
[470] H. Baker,et al. Human melanotransferrin (p97) has only one functional iron‐binding site , 1992, FEBS letters.
[471] E. Morgan,et al. Transferrin and Iron Uptake by the Brain: Effects of Altered Iron Status , 1991, Journal of neurochemistry.
[472] A. Vanin. Endothelium‐derived relaxing factor is a nitrosyl iron complex with thiol ligands , 1991, FEBS letters.
[473] J. Covès,et al. Inactivation of ribonucleotide reductase by nitric oxide. , 1991, Biochemical and biophysical research communications.
[474] T. Cox,et al. Human erythroid 5‐aminolevulinate synthase: promoter analysis and identification of an iron‐responsive element in the mRNA. , 1991, The EMBO journal.
[475] D. Richardson,et al. The uptake of inorganic iron complexes by human melanoma cells. , 1991, Biochimica et biophysica acta.
[476] D. Ben-shachar,et al. The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons , 1991, Journal of neurochemistry.
[477] P Riederer,et al. Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.
[478] B. Giometto,et al. Transferrin receptors in rat central nervous system An immunocytochemical study , 1990, Journal of the Neurological Sciences.
[479] C. Stout,et al. Structure of activated aconitase: formation of the [4Fe-4S] cluster in the crystal. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[480] D. Richardson,et al. The uptake of iron and transferrin by the human malignant melanoma cell. , 1990, Biochimica et biophysica acta.
[481] J. Langston,et al. Effects of 1‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine and 1 ‐Methyl‐4‐Phenylpyridinium Ion on ATP Levels of Mouse Brain Synaptosomes , 1990, Journal of neurochemistry.
[482] G. Brittenham. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. , 1990, Seminars in hematology.
[483] C. Marsden,et al. Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.
[484] J. Lancaster,et al. EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[485] J. Drapier,et al. IFN-gamma-activated macrophages: detection by electron paramagnetic resonance of complexes between L-arginine-derived nitric oxide and non-heme iron proteins. , 1990, Biochemical and biophysical research communications.
[486] Y. Hwang,et al. Manganese induced parkinsonism: an outbreak due to an unrepaired ventilation control system in a ferromanganese smelter. , 1989, British journal of industrial medicine.
[487] J. Parks,et al. Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.
[488] M. Graeber,et al. Increase of transferrin receptors and iron uptake in regenerating motor neurons , 1989, Journal of neuroscience research.
[489] J. Connor,et al. Do oligodendrocytes mediate iron regulation in the human brain? , 1989, Annals of neurology.
[490] C. Marsden,et al. Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.
[491] C H Ngim,et al. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease. , 1989, Neuroepidemiology.
[492] S. Hjorth,et al. Synthesis and Release of Dopamine in Rat Brain: Comparison Between Substantia Nigra Pars Compacta, Pars Reticulata, and Striatum , 1989, Journal of neurochemistry.
[493] P. Sadler,et al. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. , 1989, The Journal of biological chemistry.
[494] D. Richardson,et al. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. , 1988, Biochimica et biophysica acta.
[495] A. Graybiel,et al. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.
[496] Lukas C. Kühn,et al. A stem-loop in the 3′ untranslated region mediates iron-dependent regulation of transferrin receptor mRNA stability in the cytoplasm , 1988, Cell.
[497] R D Klausner,et al. Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. , 1988, Science.
[498] P. Riederer,et al. Tyrosine Hydroxylase Activity in Caudate Nucleus from Parkinson's Disease: Effects of Iron and Phosphorylating Agents , 1988, Journal of neurochemistry.
[499] C. Marsden,et al. INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.
[500] N. Saunders,et al. Cellular distribution of transferrin immunoreactivity in the developing rat brain , 1987, Neuroscience Letters.
[501] B. Bloch,et al. Transferrin gene expression in choroid plexus of the adult rat brain , 1987, Brain Research Bulletin.
[502] J. Hibbs,et al. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. , 1987, Science.
[503] B. Bregman,et al. Immunocytochemical distribution of transferrin and its receptor in the developing chicken nervous system. , 1986, Brain research.
[504] Voon Wee Yong,et al. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients , 1986, Neuroscience Letters.
[505] W. Nicklas,et al. Studies on the Neurotoxicity of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine: Inhibition of NAD‐Linked Substrate Oxidation by Its Metabolite, 1‐Methyl‐4‐Phenylpyridinium , 1986, Journal of neurochemistry.
[506] J. Connor,et al. The distribution of transferrin immunoreactivity in the rat central nervous system , 1986, Brain Research.
[507] B. Bloch,et al. Transferrin gene expression visualized in oligodendrocytes of the rat brain by using in situ hybridization and immunohistochemistry. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[508] C. Pert,et al. Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[509] I. Pastan,et al. Kinetics of transit of transferrin and epidermal growth factor through clathrin-coated membranes , 1984, Cell.
[510] W. Jefferies,et al. Transferrin receptor on endothelium of brain capillaries , 1984, Nature.
[511] J. Hibbs,et al. Iron depletion: possible cause of tumor cell cytotoxicity induced by activated macrophages. , 1984, Biochemical and biophysical research communications.
[512] E. Gelfand,et al. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation , 1984 .
[513] R. Duvoisin,et al. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.
[514] K. Chiba,et al. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.
[515] B. Iacopetta,et al. The kinetics of transferrin endocytosis and iron uptake from transferrin in rabbit reticulocytes. , 1983, The Journal of biological chemistry.
[516] A. Ciechanover,et al. pH and the recycling of transferrin during receptor-mediated endocytosis. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[517] R. Klausner,et al. Receptor-mediated endocytosis of transferrin and the uptake of fe in K562 cells: identification of a nonlysosomal acidic compartment. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[518] R. Doolittle,et al. Human melanoma-associated antigen p97 is structurally and functionally related to transferrin , 1982, Nature.
[519] J. Glowinski,et al. Dendritic release of dopamine in the substantia nigra , 1981, Nature.
[520] P. Ponka,et al. Biliary Iron Excretion in Rats following Pyridoxal Isonicotinoyl Hydrazone , 1980, British journal of haematology.
[521] J. Brown,et al. Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[522] P. Ponka,et al. Mobilization of iron from reticulocytes , 1979, FEBS letters.
[523] I. Fidler,et al. Depression of macrophages in mice drinking hyperchlorinated water , 1977, Nature.
[524] A Jacobs,et al. Low molecular weight intracellular iron transport compounds. , 1977, Blood.
[525] H. Chapman,et al. Macrophage tumor killing: influence of the local environment. , 1977, Science.
[526] M Sarić,et al. Occupational exposure to manganese. , 1977, British journal of industrial medicine.
[527] J. D. Parkes,et al. "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY , 1976, The Lancet.
[528] M. Schlabach,et al. The reaction of ferric salts with transferrin. , 1973, The Journal of biological chemistry.
[529] Owen Ca. Effects of iron on copper metabolism and copper on iron metabolism in rats , 1973 .
[530] A. Diosy. Monoamine oxidase inhibitors , 1984 .
[531] E. Frieden,et al. The mobilization of iron from the perfused mammalian liver by a serum copper enzyme, ferroxidase I. , 1971, The Journal of biological chemistry.
[532] G. R. Lee,et al. The role of ceruloplasmin in iron metabolism. , 1970, The Journal of clinical investigation.
[533] T. Reese,et al. JUNCTIONS BETWEEN INTIMATELY APPOSED CELL MEMBRANES IN THE VERTEBRATE BRAIN , 1969, The Journal of cell biology.
[534] E. Frieden,et al. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. , 1966, The Journal of biological chemistry.
[535] Preethi Philomina,et al. Neuroferritinopathy , 2020 .
[536] G. Töpfer. Transferrin , 2019, Springer Reference Medizin.
[537] Hana Jansová,et al. Cardioprotective Potential of Iron Chelators and Prochelators. , 2019, Current medicinal chemistry.
[538] L. Banci,et al. Intracellular metal binding and redox behavior of human DJ-1 , 2017, JBIC Journal of Biological Inorganic Chemistry.
[539] G. Di Trapani,et al. The Multifaceted Roles of DJ-1 as an Antioxidant. , 2017, Advances in experimental medicine and biology.
[540] M. Mouradian,et al. Regulation of Signal Transduction by DJ-1. , 2017, Advances in experimental medicine and biology.
[541] Christine Klein,et al. Genetics of Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.
[542] K. Takata,et al. Protection against dopaminergic neurodegeneration in Parkinson's disease-model animals by a modulator of the oxidized form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7. , 2011, Journal of pharmacological sciences.
[543] E. Rizzarelli,et al. Neurodegeneration: Metallostasis and Proteostasis , 2011 .
[544] B. Hyman,et al. Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. , 2010, Biochemical and biophysical research communications.
[545] D James Surmeier,et al. What causes the death of dopaminergic neurons in Parkinson's disease? , 2010, Progress in brain research.
[546] George Perry,et al. Oxidative stress and neurotoxicity. , 2008, Chemical research in toxicology.
[547] N. Andrews. When is a heme transporter not a heme transporter? When it's a folate transporter. , 2007, Cell metabolism.
[548] Hui Yang,et al. Environmental toxins and α-synuclein in Parkinson’s disease , 2007, Molecular Neurobiology.
[549] P. Buehler,et al. CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. , 2006, Blood.
[550] M. Núñez,et al. Iron dyshomeostasis in Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.
[551] E. Hansson,et al. Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.
[552] Nobutaka Hattori,et al. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. , 2005, Human molecular genetics.
[553] T. Araki,et al. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. , 2005, Medical science monitor : international medical journal of experimental and clinical research.
[554] G. Reynolds,et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.
[555] P. Ponka,et al. Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. , 2005, Blood.
[556] J. Joseph,et al. Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. , 2004, The Journal of biological chemistry.
[557] T. Hastings,et al. Could a loss of alpha-synuclein function put dopaminergic neurons at risk? , 2004, Journal of neurochemistry.
[558] N. Weiner,et al. Tyrosine hydroxylase regulation in the central nervous system , 2004, Molecular and Cellular Biochemistry.
[559] D. D. Di Monte. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet. Neurology.
[560] D. Richardson,et al. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[561] M. Zigmond,et al. A role for alpha-synuclein in the regulation of dopamine biosynthesis. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[562] James Parkinson,et al. An essay on the shaking palsy. 1817. , 2002, The Journal of neuropsychiatry and clinical neurosciences.
[563] B. Halliwell,et al. Role of Free Radicals in the Neurodegenerative Diseases , 2001, Drugs & aging.
[564] S. Paik,et al. Structural changes in α‐synuclein affect its chaperone‐like activity in vitro , 2000, Protein science : a publication of the Protein Society.
[565] P. Lansbury,et al. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. , 2000, Annals of the New York Academy of Sciences.
[566] C. Beaumont,et al. Function and regulation of transferrin and ferritin. , 1998, Seminars in hematology.
[567] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[568] A. Vanin. Dinitrosyl iron complexes and S-nitrosothiols are two possible forms for stabilization and transport of nitric oxide in biological systems. , 1998, Biochemistry. Biokhimiia.
[569] T. Shima,et al. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. , 1997, Free radical biology & medicine.
[570] R. Fine,et al. Development of transferrin‐positive oligodendrocytes in the rat central nervous system , 1987, Journal of neuroscience research.
[571] E. Morgan,et al. Transferrin, biochemistry, physiology and clinical significance , 1981 .
[572] P. Reichard,et al. Reduction of ribonucleotides. , 1979, Annual review of biochemistry.